Sebastian Luger1, Jens Witsch2, Andreas Dietz3, Gerhard F Hamann4, Jens Minnerup5, Hauke Schneider6, Matthias Sitzer7, Katja E Wartenberg8, Marion Niessner9, Christian Foerch10. 1. Department of Neurology, Goethe-University, Frankfurt am Main, Germany. 2. Charité Center for Stroke Research Berlin (CSB), Berlin, Germany. 3. Department of Neurology, Hochtaunus-Kliniken, Bad Homburg, Germany. 4. Department of Neurology, Horst Schmidt Klinikum, Wiesbaden, Germany & Department of Neurology and Neurological Rehabilitation, Bezirkskrankenhaus Günzburg, Germany. 5. Department of Neurology, Universitätsklinikum Münster, Germany. 6. Department of Neurology, Universitätsklinikum Carl Gustav Carus, Dresden, Germany. 7. Department of Neurology, Klinikum Herford, Herford, Germany. 8. Department of Neurology, Universitätsklinikum Halle/Saale, Germany. 9. Roche Diagnostics GmbH, Penzberg, Germany. 10. Department of Neurology, Goethe-University, Frankfurt am Main, Germany; foerch@em.uni-frankfurt.de.
Abstract
BACKGROUND: Recent studies have suggested that glial fibrillary acidic protein (GFAP) serum concentrations distinguish between intracerebral hemorrhage (ICH) and ischemic stroke (IS) shortly after symptom onset. In this prospective multicenter trial we validated GFAP in an independent patient cohort and assessed the quantitative relationship between GFAP release, bleeding size, and localization. METHODS: We included patients with a persistent neurological deficit (NIH Stroke Scale ≥4) suggestive of stroke within 6 h of symptom onset. Blood samples were drawn at hospital admission. GFAP serum concentrations were measured using an electrochemiluminometric immunoassay. Primary endpoint was the final diagnosis established at hospital discharge (ICH, IS, or stroke mimic). RESULTS: 202 patients were included (45 with ICH, 146 with IS, 11 stroke mimics). GFAP concentrations were significantly higher in ICH than in IS patients [median (interquartile range) 0.16 μg/L (0.04-3.27) vs 0.01 μg/L (0.01-0.01), P <0.001]. A GFAP cutoff of 0.03 μg/L provided a sensitivity of 77.8% and a specificity of 94.2% in distinguishing ICH from IS and stroke mimics [ROC analysis area under the curve 0.872 (95% CI, 0.802-0.942), P <0.001]. GFAP serum concentrations were positively correlated with ICH volume. Lobar ICH volumes were larger and thus associated with higher GFAP concentrations as compared to deep ICH. CONCLUSIONS: Serum GFAP was confirmed to be a biomarker indicating ICH in patients presenting with acute stroke symptoms. Very small ICH may be missed owing to less tissue destruction.
BACKGROUND: Recent studies have suggested that glial fibrillary acidic protein (GFAP) serum concentrations distinguish between intracerebral hemorrhage (ICH) and ischemic stroke (IS) shortly after symptom onset. In this prospective multicenter trial we validated GFAP in an independent patient cohort and assessed the quantitative relationship between GFAP release, bleeding size, and localization. METHODS: We included patients with a persistent neurological deficit (NIH Stroke Scale ≥4) suggestive of stroke within 6 h of symptom onset. Blood samples were drawn at hospital admission. GFAP serum concentrations were measured using an electrochemiluminometric immunoassay. Primary endpoint was the final diagnosis established at hospital discharge (ICH, IS, or stroke mimic). RESULTS: 202 patients were included (45 with ICH, 146 with IS, 11 stroke mimics). GFAP concentrations were significantly higher in ICH than in IS patients [median (interquartile range) 0.16 μg/L (0.04-3.27) vs 0.01 μg/L (0.01-0.01), P <0.001]. A GFAP cutoff of 0.03 μg/L provided a sensitivity of 77.8% and a specificity of 94.2% in distinguishing ICH from IS and stroke mimics [ROC analysis area under the curve 0.872 (95% CI, 0.802-0.942), P <0.001]. GFAP serum concentrations were positively correlated with ICH volume. Lobar ICH volumes were larger and thus associated with higher GFAP concentrations as compared to deep ICH. CONCLUSIONS: Serum GFAP was confirmed to be a biomarker indicating ICH in patients presenting with acute stroke symptoms. Very small ICH may be missed owing to less tissue destruction.
Authors: Thomas Gattringer; Christian Enzinger; Daniela Pinter; Simon Fandler-Höfler; Markus Kneihsl; Melanie Haidegger; Sebastian Eppinger; Rina Demjaha; Arabella Buchmann; Andrea Jerkovic; Reinhold Schmidt; Michael Khalil Journal: J Neurol Date: 2022-09-03 Impact factor: 6.682
Authors: Ahmed Abdelhak; Matteo Foschi; Samir Abu-Rumeileh; John K Yue; Lucio D'Anna; Andre Huss; Patrick Oeckl; Albert C Ludolph; Jens Kuhle; Axel Petzold; Geoffrey T Manley; Ari J Green; Markus Otto; Hayrettin Tumani Journal: Nat Rev Neurol Date: 2022-02-03 Impact factor: 44.711
Authors: Cory M Willis; Antoine Ménoret; Evan R Jellison; Alexandra M Nicaise; Anthony T Vella; Stephen J Crocker Journal: Front Neurosci Date: 2017-06-15 Impact factor: 4.677
Authors: Hannah A Lumley; Darren Flynn; Lisa Shaw; Graham McClelland; Gary A Ford; Phil M White; Christopher I Price Journal: BMC Emerg Med Date: 2020-04-26